albumin binding is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-05-19. Numbers and descriptions here follow the published literature rather than marketing material.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Two related forms appear under the CJC-1295 name. The simpler analogue, commonly written as modified GRF(1-29), carries the four substitutions but no additional conjugation. The second form attaches a maleimidopropionic acid linker to a lysine residue, a modification frequently called the drug affinity complex. That linker reacts with the free thiol on serum albumin to form a covalent bond. Because albumin has a long residence time in blood, the conjugated peptide stays in circulation far longer than the unconjugated analogue.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
=== Proposed long-range version === On June 26, 1972, a long-range version of the Il-86, the Il-86D (for Russian: "дальний"; transliterated: "dal’niy"; meaning "long-range"), was ordered into development by the Soviet cabinet. Design was completed in June 1976. The Il-86D would have had a marginally extended wing span, carried additional fuel, and had a range of some 8,500 km (4,600 nmi). Later announcements stated that a version of the Il-86D with Lotarev D-18 engines had entered development in March 1975. This version would have had a 147,500 kg (325,000 lb) empty weight, a 300,000 kg/660,000 lb maximum take-off weight, a fuel capacity of some 150,000 kg (330,000 lb), a wing area of 325 m2 (5,300 ft2), and a range of 10,200 km (5,500 nmi). It evolved into the Il-96.
=== Maxim Alonso === Maxim Alonso (Nicholas Bishop) is a hedge fund manager and old family friend of Yasmin's, placed in charge of overseeing her father Charles' assets. Maxim has a tense, quasi-brotherly relationship with Yasmin throughout series 1, especially after a client meeting with him is derailed by the misbehavior of Yasmin's abusive boss Kenny. In series 2, Maxim's fund goes bankrupt, prompting him to throw an excessive, drug-fueled party where and Yasmin end up having sex. While initially continuing their tryst, Yasmin grows distant from Maxim after becoming privy to Charles' numerous extramarital affairs and subsequent NDA settlements, which she is angry at Maxim for not telling her about. Maxim later drunkenly tries to force himself on Yasmin in bed, causing her to cut ties with him. In series 3, Maxim reaches out to Yasmin while camping in Northern California to tell her that Hanani Publishing was complicit in Charles' sexual misconduct, providing several of his victims with sham jobs in exchange for their silence. He explains that the company wants to make Yasmin the face of the scandal to hide their own involvement.
== Human studies == Meso-zeaxanthin is a regular dietary component in countries where it is a major pigment used by the poultry industry, particularly in Mexico. Neither adverse nor positive effects have yet been reported. In addition, meso-zeaxanthin has been tested for efficacy, though not for safety, in small pilot studies in humans. The first study to evaluate the effects of a dietary supplement containing predominantly meso-zeaxanthin was conducted in 2007. This research confirmed that meso-zeaxanthin was effectively absorbed into the serum, and MP density was increased significantly in the supplementation group. No such increases were observed in the placebo group. In another study 19 subjects consumed a supplement composed of all three macular carotenoids, including meso-zeaxanthin, for 22 days. Results demonstrated that meso-zeaxanthin was absorbed. At the Institute of Vision Research, Waterford Institute of Technology, the Meso-zeaxanthin Ocular Supplementation Trials (MOST), have been conducted to evaluate safety, MP response, and serum carotenoid response in subjects with and without AMD, following consumption of a supplement containing all three macular carotenoids in which meso-zeaxanthin was predominant. These studies confirmed safety for human consumption of the macular carotenoids following many biological tests to assess renal and liver functions, lipid profile, hematologic profile, and markers of inflammation. Also, the MOST trials identified statistically significant increases in serum concentrations of meso-zeaxanthin and lutein from baseline.
Sources: en.wikipedia.org
Kendall was elected to the United States National Academy of Sciences in 1950, and both the American Academy of Arts and Sciences and the American Philosophical Society in 1951. Kendall's career at Mayo ended in 1951, when he reached mandatory retirement age. He moved on to Princeton University, where he was a visiting professor in the Department of Biochemistry. He remained affiliated with Princeton until his death in 1972. In addition to the Nobel Prize, Kendall received other major awards including the Lasker Award, the Passano Foundation Award and the Cameron Prize for Therapeutics of the University of Edinburgh. Kendall received the Golden Plate Award of the American Academy of Achievement in 1966. He was awarded honorary doctorates from the University of Cincinnati, Western Reserve University, Williams College, Yale University, Columbia University, National University of Ireland, and Gustavus Adolphus College.
==== Movies ==== Fantasia (1940), with lead visualist Oskar Fischinger, may have been inspired by mescaline-induced visuals. Fear and Loathing in Las Vegas (1998) starring Johnny Depp and Benicio del Toro featured mescaline use. The Matrix (1999) by the Wachowskis included a brief mention of mescaline. The Royal Tenenbaums (2001) features a character named Eli Cash (Owen Wilson) who regularly takes mescaline. Crystal Fairy & the Magical Cactus (2013) starring Michael Cera and Gaby Hoffmann was about taking mescaline in the form of the San Pedro cactus.
to clone the human beta interferon gene in bacteria and the recombinant interferon was developed as 'betaseron' and approved for the treatment of MS. Superinduction of the human beta interferon gene was also used by Israeli scientists to manufacture human beta interferon.
Sources: en.wikipedia.org
Alkylation of guanine is the principal pharmacologically relevant event underlying melphalan’s therapeutic activity. This reaction produces crosslinks either between complementary DNA strands or within a single strand, typically involving guanine–guanine or adenine–adenine pairs. Such crosslinking disrupts DNA synthesis and RNA synthesis, processes essential for cell survival, leading to cytotoxicity in both dividing and non-dividing tumor cells.
==== Decapods ==== If lobsters are injected with serotonin, they behave like dominant individuals whereas octopamine causes subordinate behavior. A crayfish that is frightened may flip its tail to flee, and the effect of serotonin on this behavior depends largely on the animal's social status. Serotonin inhibits the fleeing reaction in subordinates, but enhances it in socially dominant or isolated individuals. The reason for this is social experience alters the proportion between serotonin receptors (5-HT receptors) that have opposing effects on the fight-or-flight response. The effect of 5-HT1 receptors predominates in subordinate animals, while 5-HT2 receptors predominates in dominants.
=== 1980s === Biomedical research in the 1980s was characterized by rapid advances in molecular diagnostics and genetic engineering. In 1983, Kary Mullis invented the Polymerase Chain Reaction (PCR), a technique that enabled the exponential amplification of specific DNA sequences. PCR revolutionized medical diagnostics, forensic science, and molecular genetics. The decade was also defined by the biomedical response to the HIV/AIDS epidemic following the identification of the human immunodeficiency virus in 1983 and 1984 by Luc Montagnier, Françoise Barré-Sinoussi and Robert Gallo. Additionally, recombinant human insulin, approved in 1982, became the first commercially available medication produced through recombinant DNA technology.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.